Text Size

Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Susan G. Komen Breast Cancer Foundation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00592462
First received: January 2, 2008
Last updated: September 26, 2012
Last verified: September 2012
History of Changes
  Purpose

The objective of this pilot study is to develop and evaluate a whole body MRI technique for detecting cancer metastases. The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.


Condition Intervention
Breast Cancer
 Procedure: Whole Body MRI

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Whole Body MRI for Detection of Cancer Metastases

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Develop and evaluate a whole body MRI technique for detecting cancer metastases. [ Time Frame: 3 Years ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: December 2007
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Whole Body MRI Procedure: Whole Body MRI
The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.

  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Breast cancer patients with a high suspicion or confirmed bone metastases.

Criteria

Inclusion Criteria:

  1. Breast cancer patients with high suspicion or confirmed bone metastases.
  2. Patient who have undergone a clinically indicated skeletal scintigraphy within two weeks of the MRI exam.
  3. Patients who have signed their informed consent form to undergo the study.

Exclusion Criteria:

1) Contraindication to conventional MR imaging (e.g. metal implants, pace maker, etc.).

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00592462

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Susan G. Komen Breast Cancer Foundation
Investigators
Principal Investigator: Jingfei Ma, PhD M.D. Anderson Cancer Center
  More Information

Additional Information:
The University of Texas M.D.Anderson Cancer Center  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00592462     History of Changes
Other Study ID Numbers: 2007-0539
Study First Received: January 2, 2008
Last Updated: September 26, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Breast Cancer
Whole Body MRI
Magnetic Resonance Imaging
Metastases

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasm Metastasis
Neoplasms by Site
Neoplasms
 Breast Diseases
Skin Diseases
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on June 18, 2013